<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/421B4793-37B1-4BD6-AAD9-8B6C240ED8C9"><gtr:id>421B4793-37B1-4BD6-AAD9-8B6C240ED8C9</gtr:id><gtr:name>Duke University</gtr:name><gtr:address><gtr:line1>Edmund T Pratt</gtr:line1><gtr:postCode>27708-0300</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:department>Mechanical Engineering</gtr:department><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/421B4793-37B1-4BD6-AAD9-8B6C240ED8C9"><gtr:id>421B4793-37B1-4BD6-AAD9-8B6C240ED8C9</gtr:id><gtr:name>Duke University</gtr:name><gtr:address><gtr:line1>Edmund T Pratt</gtr:line1><gtr:postCode>27708-0300</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/EB789AD3-CE40-4D32-A033-E5D2E0EEECF7"><gtr:id>EB789AD3-CE40-4D32-A033-E5D2E0EEECF7</gtr:id><gtr:firstName>Ashley</gtr:firstName><gtr:surname>Martin</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/E152B0ED-B52B-4A39-A25E-3209A2136540"><gtr:id>E152B0ED-B52B-4A39-A25E-3209A2136540</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:otherNames>William</gtr:otherNames><gtr:surname>Hewett</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/30DAE96A-3581-461D-8EFD-C7B76473DCEA"><gtr:id>30DAE96A-3581-461D-8EFD-C7B76473DCEA</gtr:id><gtr:firstName>Shakil</gtr:firstName><gtr:surname>Ahmad</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C32E9430-021D-4676-85DE-838CD7B384A0"><gtr:id>C32E9430-021D-4676-85DE-838CD7B384A0</gtr:id><gtr:firstName>Asif</gtr:firstName><gtr:surname>Ahmed</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0600270"><gtr:id>D14B55BC-131F-412F-8C88-DCA9D399CB66</gtr:id><gtr:title>Structure function analysis of vascular endothelial growth factor receptors in angiogenesis</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0600270</gtr:grantReference><gtr:abstractText>Heart attack or stroke can block blood vessels leading to local tissue damage or even death; there is therefore a need to increase blood flow and promote circulation by making new blood vessels. In contrast, inhibiting blood vessel growth prevents cancer and blindness respectively. The formation of blood vessels (angiogenesis) is complex: They are lined with endothelial cells, which divide and re-arrange themselves into new tube-like vessels. Vascular endothelial growth factor is an essential protein for the blood vessel formation and works by binding to receptors on the endothelial cells. This project will determine how these receptors signal to co-ordinate new vessel formation. Discoveries from this study will provide new insight for the development of novel therapeutic approaches to promote or block the growth of new blood vessels.</gtr:abstractText><gtr:technicalSummary>Nitric oxide (NO) not only regulates blood vessel tone but also promotes angiogenesis. Vascular endothelial growth factor-A (VEGF) is critical for vascular development, angiogenesis and revascularisation after endothelial injury and acts via two receptors, VEGFR-1 and VEGFR-2. The loss of either receptor leads to death in utero. In contrast, the loss of VEGFR-1 catalytic activity does not impair vascular development, but inhibits pathological neovascularisation suggesting that VEGFR-1 is also important in angiogenesis-driven diseases. We hypothesise that VEGF utilises alternative signalling pathways via VEGFR-1 or VEGFR-2 to regulate NO and promote angiogenesis. We will determine the relative roles of these two receptors using chimeric receptors in which the extracellular domain of the epidermal growth factor receptor was substituted for that of VEGFR-1 or VEGFR-2 and transduced into human endothelial cells. To determine the structural-functional relationship between VEGFR-1 and VEGFR-2, NO and angiogenesis, a series of tyrosine-to-phenylalanine mutants will be analysed in NO release and capillary-like tube formation assays. A proteomic approach will be employed to identify the proteins associated with key VEGF receptor tyrosine residues that are required for eNOS activation and/or capillary morphogenesis and their downstream effectors. The downstream effectors of VEGFR-1 and VEGFR-2 and identified tyrosine residues will then be investigated by manipulating the signal transduction pathways of phosphatidylinositol 3-kinase (PI3K/PDK-1/Akt), phospholipase C-gamma1 and protein kinase C isozymes. This will be achieved by selective inhibition using either gene knockdown or over-expression of dominant-negative mutants of the signalling proteins using lentiviral and adenoviral vectors respectively. These studies will identify new sites of modulation in VEGF-mediated vascular morphogenesis and NO release that may highlight new therapeutic targets for management of vascular insufficiencies and cancer.</gtr:technicalSummary><gtr:fund><gtr:end>2009-10-01</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-10-02</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>295722</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Duke University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Dr C.D. Kontos</gtr:description><gtr:id>69CDAC48-6445-4FE2-A29B-7E089AEAEA67</gtr:id><gtr:impact>Publication in ATVB, 2007. Circulation, 2009.</gtr:impact><gtr:outcomeId>451D7C37E20-1</gtr:outcomeId><gtr:partnerContribution>Reagents over the years and joint publication.</gtr:partnerContribution><gtr:piContribution>We undertook studies on sTie2 shedding in response to VEGF in endothelial cells.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Birmingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>College of Medical and Dental Sciences</gtr:department><gtr:description>Dr David Thickett</gtr:description><gtr:id>CBAC43AA-475B-4F68-BE40-E2E67732953B</gtr:id><gtr:impact>Publication in Crit Care Med., 2007. Also Dr Thickett was awarded a Senior Clinical Fellowship from the Wellcome Trust in 2008; we have a another manuscript to complete.</gtr:impact><gtr:outcomeId>40B5FE49541-1</gtr:outcomeId><gtr:partnerContribution>Publication in Crit Care Med</gtr:partnerContribution><gtr:piContribution>Vascular endothelial growth factor promotes physical wound repair and is anti-apoptotic in primary distal lung epithelial and A549 cells.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Mayo Clinic Angiogenesis Symposium</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>5CDC3825-BAB1-4719-B53A-D633D675BE13</gtr:id><gtr:impact>International Angiogenesis Audience, including world leaders in the field.

there has been an increase awareness of the role of VEGFR-1 in angiogenesis from our studies.</gtr:impact><gtr:outcomeId>7D1867E8C2B</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>AngioNET</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>BB575C4F-12AD-401D-A844-A8013F1BAAF1</gtr:id><gtr:impact>AngioNET is a European wide researchers in biology, maths and chemistry, includes industry.

there has been an increase awareness of the role of VEGFR-1 in angiogenesis from our studies.</gtr:impact><gtr:outcomeId>EF5992F1456</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Mail Online - Breakthrough in fight against pre-eclampsia</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>8C0FC273-FB44-42AF-89E6-AD7D61B1DF54</gtr:id><gtr:impact>Breakthrough in fight against pre-eclampsia: Scientists may have found cause of the life-threatening pregnancy condition

1. Giving hydrogen sulfide can reduce the risk of pre-eclampsia
2. The chemical is found naturally in the body, but some have lower levels
3. Scientists ay that if used safely in the form of a drug it can make up for this natural shortfall and help maintain a healthy blood flow to the placenta



A lot of request for its use in women with preeclampsia; asking when could such a treatment become available to them.</gtr:impact><gtr:outcomeId>5442cba17b9641.58327489</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Trans-Institute Angiogenesis Research Program, NIH, Washington DC</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>C60D170C-0E04-4DE3-9FF7-36B326C236A7</gtr:id><gtr:impact>Trans-Institute Angiogenesis Research Program, NIH, Washington DC

Awareness of our work and discussion on the future direction of angiogenesis research in the USA.</gtr:impact><gtr:outcomeId>2EC1BB0318E</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>C0BF52E1-2E0A-4BA5-B1EF-A7375449DAE3</gtr:id><gtr:title>Vascular endothelial growth factor-induced endothelial cell proliferation is regulated by interaction between VEGFR-2, SH-PTP1 and eNOS.</gtr:title><gtr:parentPublicationTitle>Microvascular research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ad2b1e9bc82f6c5c24c365dd4a584a4f"><gtr:id>ad2b1e9bc82f6c5c24c365dd4a584a4f</gtr:id><gtr:otherNames>Cai J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0026-2862</gtr:issn><gtr:outcomeId>E9ciSBxHkpC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1C9F2F91-0730-4EF0-B3DB-52509DCACDAF</gtr:id><gtr:title>Nitric oxide-dependent bone marrow progenitor mobilization by carbon monoxide enhances endothelial repair after vascular injury.</gtr:title><gtr:parentPublicationTitle>Circulation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ba033bc7077768019119d506b1113191"><gtr:id>ba033bc7077768019119d506b1113191</gtr:id><gtr:otherNames>Wegiel B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0009-7322</gtr:issn><gtr:outcomeId>pm_13962_22_20083679</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2E616D2F-ED1D-4B4C-AF82-8B9921E35844</gtr:id><gtr:title>Direct evidence for endothelial vascular endothelial growth factor receptor-1 function in nitric oxide-mediated angiogenesis.</gtr:title><gtr:parentPublicationTitle>Circulation research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/378c2178deeae7c8e4ad76a33c2416f8"><gtr:id>378c2178deeae7c8e4ad76a33c2416f8</gtr:id><gtr:otherNames>Ahmad S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0009-7330</gtr:issn><gtr:outcomeId>4A4A83E95B9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>39EF9510-0020-49AC-8D15-1710F0AB2CA8</gtr:id><gtr:title>VEGF-E activates endothelial nitric oxide synthase to induce angiogenesis via cGMP and PKG-independent pathways.</gtr:title><gtr:parentPublicationTitle>Biochemical and biophysical research communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0215022fa505393f3ed57e409d1df60a"><gtr:id>0215022fa505393f3ed57e409d1df60a</gtr:id><gtr:otherNames>Cudmore M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0006-291X</gtr:issn><gtr:outcomeId>EDADBA63F58</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>81BE7F78-CBCB-4001-8EC3-E46E941E3BC1</gtr:id><gtr:title>Carbon monoxide inhibits sprouting angiogenesis and vascular endothelial growth factor receptor-2 phosphorylation.</gtr:title><gtr:parentPublicationTitle>Thrombosis and haemostasis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/378c2178deeae7c8e4ad76a33c2416f8"><gtr:id>378c2178deeae7c8e4ad76a33c2416f8</gtr:id><gtr:otherNames>Ahmad S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0340-6245</gtr:issn><gtr:outcomeId>545e615beafb06.13828485</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6FAECAE0-788A-487B-856C-C9C77B282D6E</gtr:id><gtr:title>Selective inhibition of the human tie-1 promoter with triplex-forming oligonucleotides targeted to Ets binding sites.</gtr:title><gtr:parentPublicationTitle>Molecular medicine (Cambridge, Mass.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d7072fd7936ad7b33546f2aaa18f2833"><gtr:id>d7072fd7936ad7b33546f2aaa18f2833</gtr:id><gtr:otherNames>Hewett PW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1076-1551</gtr:issn><gtr:outcomeId>59D5F832F94</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>22F5B92D-4B36-43EF-BEAF-489705181986</gtr:id><gtr:title>Flt1 acts as a negative regulator of tip cell formation and branching morphogenesis in the zebrafish embryo.</gtr:title><gtr:parentPublicationTitle>Development (Cambridge, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/be5026317591425446a36c3053435cbc"><gtr:id>be5026317591425446a36c3053435cbc</gtr:id><gtr:otherNames>Krueger J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0950-1991</gtr:issn><gtr:outcomeId>th61K9tLifh</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9BB06234-859A-41DD-A708-05148AA44E08</gtr:id><gtr:title>Heterodimerisation between VEGFR-1 and VEGFR-2 and not the homodimers of VEGFR-1 inhibit VEGFR-2 activity.</gtr:title><gtr:parentPublicationTitle>Vascular pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e992aab3e8840fffd19564dde9896985"><gtr:id>e992aab3e8840fffd19564dde9896985</gtr:id><gtr:otherNames>Cai M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1537-1891</gtr:issn><gtr:outcomeId>58991a795673b7.26042189</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>75DD8BA1-E105-40E8-A5D5-B0A9ABB34847</gtr:id><gtr:title>VEGF induces Tie2 shedding via a phosphoinositide 3-kinase/Akt dependent pathway to modulate Tie2 signaling.</gtr:title><gtr:parentPublicationTitle>Arteriosclerosis, thrombosis, and vascular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bcce5ca362a3cc4e09cd3a2a2ffaee9f"><gtr:id>bcce5ca362a3cc4e09cd3a2a2ffaee9f</gtr:id><gtr:otherNames>Findley CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1079-5642</gtr:issn><gtr:outcomeId>BA0341D13FB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FA7618D2-C69A-4251-9409-EE740A91BCC6</gtr:id><gtr:title>The release of nitric oxide from S-nitrosothiols promotes angiogenesis.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/62f873f073f3e3dc32f6d6711448ce11"><gtr:id>62f873f073f3e3dc32f6d6711448ce11</gtr:id><gtr:otherNames>Al-Ani B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>30ECBD7C22C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E72526D8-693F-43DE-AC0E-A85A59982860</gtr:id><gtr:title>Hepatitis C virus infection reduces hepatocellular polarity in a vascular endothelial growth factor-dependent manner.</gtr:title><gtr:parentPublicationTitle>Gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d9e444d2922dd043f966085965c94caa"><gtr:id>d9e444d2922dd043f966085965c94caa</gtr:id><gtr:otherNames>Mee CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0016-5085</gtr:issn><gtr:outcomeId>437B171A003</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4508EED9-EC27-450D-9ADB-36680E7E9029</gtr:id><gtr:title>Vascular endothelial growth factor promotes physical wound repair and is anti-apoptotic in primary distal lung epithelial and A549 cells.</gtr:title><gtr:parentPublicationTitle>Critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7b130435df706169f3b130b5a305e853"><gtr:id>7b130435df706169f3b130b5a305e853</gtr:id><gtr:otherNames>Roberts JR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0090-3493</gtr:issn><gtr:outcomeId>847A195AE61</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6B584714-D2AA-4D25-8645-024565080576</gtr:id><gtr:title>Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1.</gtr:title><gtr:parentPublicationTitle>Circulation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0215022fa505393f3ed57e409d1df60a"><gtr:id>0215022fa505393f3ed57e409d1df60a</gtr:id><gtr:otherNames>Cudmore M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0009-7322</gtr:issn><gtr:outcomeId>FDB35F11FD1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F1830EEF-3186-4E71-A2FF-23FFCF3BA1BB</gtr:id><gtr:title>Unravelling the theories of pre-eclampsia: are the protective pathways the new paradigm?</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5b268a5b4f18e012b49c9c4df08170ee"><gtr:id>5b268a5b4f18e012b49c9c4df08170ee</gtr:id><gtr:otherNames>Ahmed A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn><gtr:outcomeId>5442c4521465e0.62586365</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0600270</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>